OFFEN
Erkankung Akronym/Sponsor PatientInnengruppe Local PI
NSCLC PEARLS (Keynote 091) Post-op, +/-adj. Chemoth OA Dr. Pall
Pankreas ABCSGP02 loc. advanced, inop., neoadj. OÄ. Dr.in Djanani
NSCLC Hudson Biomarker-driven therapy bei PD. Dr. Pircher
IO-Resistenz
IN BÄLDE OFFEN:
NSCLC Keynote 867 Inop. St I+IIA OA Dr. Pall
NSCLC MSD 1st Line St IV NSCLC/Pembro+Taxol OA Dr. Pall
gefolgt von Pembro +/- Olaparib Maint.
NSCLC MSD 1st Line St IV NSCLC/Pembro+Platin OA Dr. Pall
Pembro+Olaparib vs Pemetrex Maint.
NSCLC KRASmut AMG510 KRASmut-specific mAb OA Dr. Pall
Met. CRC Solstice 1st Line Lonsurf/Beva vs Cape/Beva OA Dr. Amann